Attendee search 

TheraIndx Life Sciences is a preclinical Contract Research Services Company based in Bangalore, India with Management team who have worked in Global Pharma in Drug Discovery and development progressing molecules from discovery to clinic. TheraIndx offers modular and integrated drug Discovery and development services to Pharma, Biotech and academic institutions across the globe. TheraIndx offers a wide range of animal disease models in infection, oncology, CNS and metabolic disorders along with Biomarker assays. Our Business models are Fee for services and also in partnerships till IND filing.

CICCB is an investment company, cofounded by China International Capital Corporation Limited (‘CICC’) and CCB Trust Co., Ltd. CICC is the No.1 investment bank in China which was founded in 1995 as a joint venture of China Construction Bank and Morgan Stanley. And CCB trust is the No.1 trust in China, with AUM more than 250 bn USD. In addition, CCB trust is the wholly owned subsidiary of China Construction Bank, one of Top 4 state owned banks in China. Our main business covers asset management, IPO, M&A and strategic investment for industry. Leveraged by shareholders' strong resource, CICCB's investment areas cover full value chain, including VC, PE, pre-IPO and other stages. Target industries include healthcare, TMT, consumer-related and other emerging strategic industries. As a strategic integration platform for CICC and CCB, CICCB is committed to becoming an all-round asset management institution with global influence in key areas.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. An IND was filed with favorable responses of communication from FDA were received in 2018 and 2020. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in Q2 2021. Additional products are in encapsulation feasibility studies. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy. On the same platform, additional active drugs with solubility and / or acute toxicity issues were successfully formulated to greatly improve delivery efficacy and safety.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 20 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. Co-founder and CSO Dr. Jun Li has many years of experience in innovative drug delivery system. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

Elasmogen, a next generation biologics company, develops soloMERs which are high affinity binding, single-domains; they are small (9% of an antibody), highly stable proteins and crucially are outside the complex/competitive antibody patent landscape. soloMERs are pre-disposed to generating potent neutralisers by binding to novel or cryptic epitopes. Their small size makes them ideal for both site-specific delivery and penetration of solid tumours. Our lead product, ADCP165, is an anti-ROR1 soloMER drug conjugate being co-developed with Almac Discovery. This program is tracking for entry into the clinic 2022/3 with follow on products in the pipeline. In addition our lead anti-auto-immune inflammatory domain, ELN/22, a tetravalent, bi-paratopic anti-TNF product is being developed for oral delivery for the treatment of IBD.
We are currently looking for partners for our existing assets and also companies who would like to access our powerful, patent protected soloMER platform to develop new products.

Otomagnetics is a biotechnology Company developing a non-invasive platform technology to deliver drugs and other therapeutic payloads to the inner and middle ear compartments, eye and skin. The link to the explainer video on the technology is provided below.

https://www.youtube.com/watch?v=1go9HYjMlFk&feature=youtu.be

SYNSIGHT developed the first drug discovery platform combining cell-based microscopy that train AI models, to generate new chemical entities. Your benefits will be to increase the productivity of your R&D and secure your drug discovery programs.

Our innovative platform and our technologies can be directly applied to protein-protein or protein-RNA interactions. Our bioassay is unique and patented and is able to qualify and quantify these interactions directly in human cell, and also of course the efficacy of small molecule modulators (Hit identification, "in cell IC50" measurement). This assay, easy to setup as medium or high-throughput screening level, is then able to train our AI models which generate new molecules.

We already successfully used our platform to study oncologic and neurodegenerative targets, for our own R&D or for customers. Our platform is able to manage different therapeutic area (oncology, virology, neurology, …), and different targets from your portfolio. We also propose to feed your portfolio and develop screening setup of our platform with exclusivity, with innovative targets like TPD-43, YB-1, alpha-SYN, BCL2, HUR, …

We are a start-up company with a Phase III ready small molecule drug for the treatment of aortic valve stenosis. We

We licensed the drug from the Mayo Clinic and the drug has been part of the NIH's NCAT's Program in which they put in $5 million for our Phase I and Phase II clinical trials and Sanofi put in another $1 million for manufacturing.

We are raising a Series A round now and we welcome interest from Chinese investors and partners.

You can reach me at 858-205-5091.

Thanks.

----Randy Berholtz

Life Sciences venture capital fund with three funds under management.